Cecilia Jones - Mar 1, 2022 Form 4 Insider Report for LogicBio Therapeutics, Inc. (LOGC)

Role
Chief Financial Officer
Signature
/s/ Andrea Paul, as Attorney-in-Fact
Stock symbol
LOGC
Transactions as of
Mar 1, 2022
Transactions value $
$0
Form type
4
Date filed
3/3/2022, 05:05 PM
Previous filing
Jan 13, 2022
Next filing
Sep 28, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LOGC Stock Option (right to buy) Award $0 +112K $0.00 112K Mar 1, 2022 Common Stock 112K $0.70 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan.
F2 The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Company on each vesting date.